X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Natco Pharma with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs TEVA PHARMA (Israel) - Comparison Results

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 NATCO PHARMA   TEVA PHARMA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
TEVA PHARMA
Dec-13
NATCO PHARMA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs8772,663-   
Low Rs4242,313-   
Sales per share (Unadj.) Rs223.41,528.1-  
Earnings per share (Unadj.) Rs31.195.5-  
Cash flow per share (Unadj.) Rs40.3219.0-  
Dividends per share (Unadj.) Rs5.0083.56-  
Dividend yield (eoy) %0.83.4 22.9%  
Book value per share (Unadj.) Rs219.51,697.4-  
Shares outstanding (eoy) m33.07848.00-   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.91.6 178.8%   
Avg P/E ratio x20.926.1 80.3%  
P/CF ratio (eoy) x16.111.4 142.1%  
Price / Book Value ratio x3.01.5 202.1%  
Dividend payout %16.187.5 18.4%   
Avg Mkt Cap Rs m21,5042,109,663 1.0%   
No. of employees `000NA44.9 0.0%   
Total wages/salary Rs m1,1280-   
Avg. sales/employee Rs ThNM28,831.5-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM1,801.1-  
INCOME DATA
Net Sales Rs m7,3891,295,830 0.6%  
Other income Rs m1670-   
Total revenues Rs m7,5561,295,830 0.6%   
Gross profit Rs m1,793354,864 0.5%  
Depreciation Rs m304104,743 0.3%   
Interest Rs m36625,452 1.4%   
Profit before tax Rs m1,290224,668 0.6%   
Minority Interest Rs m461,021 4.5%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-147,482 0.0%   
Tax Rs m309-2,743 -11.3%   
Profit after tax Rs m1,02780,950 1.3%  
Gross profit margin %24.327.4 88.6%  
Effective tax rate %23.9-1.2 -1,960.4%   
Net profit margin %13.96.2 222.6%  
BALANCE SHEET DATA
Current assets Rs m3,681875,199 0.4%   
Current liabilities Rs m3,123763,247 0.4%   
Net working cap to sales %7.68.6 87.5%  
Current ratio x1.21.1 102.8%  
Inventory Days Days8991 98.6%  
Debtors Days Days5996 61.2%  
Net fixed assets Rs m7,685423,247 1.8%   
Share capital Rs m3313,190 10.4%   
"Free" reserves Rs m6,6700-   
Net worth Rs m7,2591,439,421 0.5%   
Long term debt Rs m955662,587 0.1%   
Total assets Rs m11,9572,961,387 0.4%  
Interest coverage x4.59.8 46.0%   
Debt to equity ratio x0.10.5 28.6%  
Sales to assets ratio x0.60.4 141.2%   
Return on assets %11.73.6 324.4%  
Return on equity %14.25.6 251.7%  
Return on capital %20.74.9 420.3%  
Exports to sales %39.40-   
Imports to sales %5.70-   
Net fx Rs m2,7430-   
CASH FLOW
From Operations Rs m1,440206,488 0.7%  
From Investments Rs m-1,089-73,167 1.5%  
From Financial Activity Rs m-353-247,697 0.1%  
Net Cashflow Rs m-1-114,375 0.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 63.79 Rs / USD

Compare NATCO PHARMA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare NATCO PHARMA With: AJANTA PHARMA  SUN PHARMA  ORCHID PHARMA LTD  UNICHEM LAB  AUROBINDO PHARMA  



Today's Market

Sensex Breaches 36,000 Mark; ONGC Nears 52-Week High(Closing)

The NSE Nifty on Tuesday sailed past the 11,000 mark, while the BSE Sensex breached the 36,000 level for the first time after an IMF report showed India was set to regain.

Related Views On News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Jan 23, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS